Insight on the NHL and the world of hockey. Sign up to our newsletter. You will receive backstage access to special features, articles, promotions, special events. Includes news, weather, sports, local events, and air schedules. In ice hockey, an official is a person who has some responsibility in enforcing the rules and maintaining the order of the game. There are two categories of officials. Boomer gets you primed and ready to go for a night of NHL action. From lineup matchups to fantasy duds and studs. Non- Hodgkin Lymphoma (NHL) Treatment Regimens: Diffuse Large B- Cell Lymphoma. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines. Available at: http: //www. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long- term outcome of patients in the LNH- 9. CHOP to standard CHOP chemo- therapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. ![]() Feugier P, Van Hoof A, Sebban C, et al, Long- term results of the R- CHOP study in the treatment of elderly patients with diffuse large B- cell lymphoma: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP- like chemotherapy plus rituximab versus CHOP- like chemotherapy alone in young patients with good- prognosis diffuse large- B- cell lymphoma: a randomised controlled trial by the Mab. ![]() ![]() Thera International Trial (MIn. T) Group. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi- weekly CHOP- 1. CD2. 0+ B- cell lymphomas: a randomized controlled trial (RICOVER- 6. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B- cell non- Hodgkin lymphoma: a phase 3 comparison of dose intensification with 1. Purroy N, Lopez A, Vallespi T, et al. The NHL on NBC is a presentation of National Hockey League (NHL) games that are produced by NBC Sports, and televised on NBC and NBCSN in the United States. If you would like to learn more, please enter your e-mail below to receive news alerts, event info or other promotions. ReverbNation helps Artists grow lasting careers by introducing them to music industry partners, exposing them to fans, and building innovative tools to promote their. ![]() Dose- adjusted EPOCH plus rituximab (DA- EPOCH- R) in untreated patients with poor risk large B- cell lymphoma. A phase 2 study conducted by the Spanish PETHEMA Group . Abstract 2. 70. 1. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose- adjusted EPOCH and rituximab in untreated diffuse large B- cell lymphoma with analysis of germinal center and post- germinal center biomarkers. Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi- center study of DA- EPOCH- rituximab in untreated diffuse large B- cell lymphoma with analysis of outcome by molecular subtype. Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): An effective and well- tolerated regimen in poor- risk, aggressive non- Hodgkin's lymphoma. Sports journalists and bloggers covering NFL, MLB, NBA, NHL, MMA, college football and basketball, NASCAR, fantasy sports and more. News, photos, mock drafts, game.Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B- cell lymphoma: results from a prospective phase II study. Zaja F, Tomadini V, Zaccaria A, et al. CHOP- rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B- cell lymphoma. Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B- cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. Garcia- Suarez J, Banas H, Arribas I, et al. Dose- adjusted EPOCH plus rituximab is an effective regimen in patients with poor- prognostic untreated diffuse large B- cell lymphoma: results from a prospective observational study. British Journal of Haematology. Moccia AA, Schaff K, Hoskins P, et al. R- CHOP with etoposide substituted for doxorubicin (R- CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindi- cation to anthracyclines. Presented at: 5. 1st American Society of Hematology Annual Meeting and Exposition; December 7, 2. New Orleans, LA. 2. Abstract 4. 08. 1. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R- mini. CHOP) in elderly patients older than 8. B- cell lymphoma: a multicentre, single- arm, phase 2 trial. Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U. S./ Canadian intergroup trial (SWOG S9. CHOP . Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high- dose Ara- C and dexamethasone (DHAP). Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high- dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non- Hodgkin's lymphoma. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B- cell lymphoma in the rituximab era. Velasquez WS, Mc. Laughlin P, Tucker S, et al. Martin A, Conde E, Arnan M, et al. R- ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B- cell lymphoma: the influence of prior exposure to rituximab on outcome. Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B- cell non- Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC- CTG). Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi- center phase II study by the Puget Sound Oncology Consortium. Lopez A, Gutierrez A, Palacios A, et al. GEMOX- R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large- cell lymphoma: a phase II study. Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)- based second- line chemotherapy for the management of relapsed and refractory aggressive non- Hodgkin's lymphoma. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE (RICE) as second- line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B- cell lymphoma. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B- cell lymphoma in the rituximab era. Dincol D, Buyukcelik A, Dogan M, et al. Long- term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non- Hodgkin lymphoma responding to CHOP. Emmanouilides C, Lill M, Telatar M, et al. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non- Hodgkin's lymphoma. Vacirca J, Tabbara I, Acs P, Shumaker G. Bendamustine + rituximab as treatment for elderly patients with relapsed or refractory diffuse large B- cell lymphoma . Abstract 2. 80. 6. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B- cell lymphoma. Bartlett N, Sharman J, Oki Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD3. Hodgkin lymphomas: interim results in patients with DLBCL and other B- cell lymphomas . Abstract: 8. 48. 3. Yan L, Yimamu M, Wang X, et al. Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non- germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl- 2 expression. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin- containing regimen in relapsed and resistant lymphomas: An 8- year follow- up study of EPOCH. Jermann M, Jost LM, Taverna C, et al. Rituximab- EPOCH, an effective salvage therapy for relapsed, refractory or transformed B- cell lymphomas: Results of a phase II study. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed or aggressive B- cell lymphoma. Gopal A, Press O, Pagel J. Efficacy and Safety of Gemcitabine (G), Carboplatin . Corazzelli G, Capobianco G, Arcamone M, et al. Long- term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant- ineligible patients with refractory/relapsing B- cell lymphoma. Cancer Chemother Pharmacol. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B- cell lymphoma not candidates for high- dose therapy. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single- agent lenalidomide for relapsed or refractory aggressive B- cell non- Hodgkin's lymphoma. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive Non- Hodgkin's lymphoma. Wang M, Fowler N, Wagner- Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. South San Francisco, CA.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
August 2017
Categories |